Adaptogenics names Antoun Nabhan president

Adaptogenics Appoints Antoun Nabhan as President

(TheNewswire)

Former executive at Onyx Pharmaceuticals, Raptor Pharmaceuticals and Soleno Therapeutics brings experience across more than $2 billion in healthcare transactions and two Nasdaq IPO processes

Vancouver, British Columbia – TheNewswire - October 13, 2026 — Adaptogenics Health Corp. (CSE: ADPT) (“Adaptogenics” or the “Company”) is pleased to announce the appointment of Antoun Nabhan, J.D., as President, effective October 1, 2026.

Mr. Nabhan brings nearly two decades of healthcare investment, corporate finance and business development experience. He has led or advised on more than $2 billion in buy side healthcare transactions involving multiple assets that subsequently received regulatory approval, including Kyprolis, Stivarga, Quinsair and Somryst.

Mr. Nabhan previously served as Senior Vice President at Oaktree Capital Management, L.P. and currently manages a portfolio of publicly traded healthcare equities at Sagamore Bioventures, bringing institutional investment experience to the Company’s leadership team. His operating roles include Chief Financial Officer of Establishment Labs and Vice President of Corporate Development at Pear Therapeutics, Raptor Pharmaceuticals and Capnia, now Soleno Therapeutics. His background spans pharmaceutical assets, medical devices and prescription digital therapeutics.

Across his roles at Establishment Labs and Soleno Therapeutics, formerly Capnia, Inc., Mr. Nabhan led two Nasdaq initial public offering processes. He also held transactional executive roles at Onyx Pharmaceuticals before its acquisition by Amgen and Raptor Pharmaceuticals before its acquisition by Horizon Pharma. He has also cofounded three pharmaceutical development companies, two of which, Convivia and Incellico, have been acquired.

Mr. Nabhan holds a J.D. from Harvard Law School and an A.B. from the University of Chicago, where he graduated Phi Beta Kappa.

As President, Mr. Nabhan will lead the identification, evaluation and negotiation of asset acquisitions, licensing partnerships and strategic collaborations. He will work with Chief Executive Officer Dr. J. David Warren to connect scientific evaluation with transaction structure and capital planning as the Company pursues proprietary peptide and small molecule opportunities.

“Antoun knows how to identify promising assets, negotiate the rights that matter and build the partnerships needed to advance them,” said Dr. Warren. “His experience complements our scientific capabilities and will be important as we build a portfolio with meaningful commercial potential.”

“The opportunity is to bring strong science and thoughtful dealmaking together,” said Mr. Nabhan. “I look forward to working with David and this very talented team to secure differentiated assets and develop them with scientific rigor and a disciplined use of capital.”

About Adaptogenics Health Corp.

Adaptogenics Health Corp. (CSE: ADPT) is a Canadian-based nutraceutical company focused on the formulation and distribution of functional mushroom products and nutritional supplement alternatives. The Company intends to evaluate opportunities to establish a proprietary pipeline of peptide and small molecule therapeutics focused on metabolic health, muscle preservation and inflammation. Led by an experienced scientific and business team, the Company combines asset acquisition and licensing with targeted discovery and delivery research to create differentiated therapeutic candidates and defensible intellectual property. Adaptogenics also maintains its existing nutraceutical business and is evaluating complementary GLP-1 companion product opportunities

 

Cautionary Note Regarding Forward-Looking Information This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information in this news release includes, without limitation, statements regarding the Company's strategy and intended business direction; the continuation of its nutraceutical business; potential GLP-1 companion nutraceutical products; the evaluation, licensing, acquisition, design and development of therapeutic candidates; research activities and collaborations; the use of computational design tools; the generation of intellectual property; and the timing and content of future updates. Forward-looking information is based on management's reasonable assumptions, estimates, expectations and opinions as of the date of this news release. These include assumptions that the Company will be able to identify and acquire or license suitable candidates on acceptable terms, obtain sufficient financing, retain key personnel, continue its nutraceutical operations, and obtain all required regulatory, stock exchange and shareholder approvals. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. These include scientific, preclinical and clinical development risks; regulatory requirements applicable to therapeutics and natural health products; the availability of financing; the ability to complete transactions and to secure and protect intellectual property; competition; dependence on key personnel; and the risks described in the Company's continuous disclosure filings available under its profile on SEDAR+. Readers are cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information except as required by applicable securities laws. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release..

Copyright (c) 2026 TheNewswire - All rights reserved.